Our Commitment to Patients

Rare skin disorders like epidermolysis bullosa (EB), epidermolysis ichthyosis (EI), and scleroderma can take a devastating toll on patients and their families. Fragile, blistering, scaling, or hardening skin can be painful, and in many cases can lead to further complications. 

At BioMendics, we’re committed to developing safe and effective treatments for these conditions. 

Further testing is needed, and Stanford University School of Medicine’s Department of Dermatology is currently recruiting for a clinical trial in epidermolysis bullosa simplex. If you suffer from this condition,talk to your doctor about whether this 10-week trial is right for you. You can also learn more about clinical trials here. We are committed to working with the EB and other patient communities to better understand these diseases, the toll they take on patients, and what patients want from our treatments in development.

Together, we share the goal of making the blisters, wounds, pain, and itch of these diseases a thing of the past.